NCT07023068Enrolling by invitationEarly phase 1
⁶⁸Ga-DPA in the Lung Cancer Diagnosis
Clinical Application of PD-L1 Targeted Imaging Agent ⁶⁸Ga-DPA in the Diagnosis of Lung Cancer
Source: ClinicalTrials.gov · Last updated 15 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile and excellent imaging performance. Leveraging the established strengths of the Department of Nuclear Medicine at Peking Union Medical College Hospital, we now plan to conduct an exploratory PET/CT imaging study in lung cancer patients. This study aims to provide an in vivo, non-invasive, and visualizable technique for detecting PD-L1 expression levels and spatial distribution in tumors. It will further validate the clinical utility of this technology, offering critical diagnostic insights for initial assessment and treatment efficacy evaluation in PD-L1-positive tumor patients undergoing PD-L1-targeted therapies.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 8 Jun 2025
- Start date
- 28 Sept 2024
- Primary completion date
- 28 Sept 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07023068
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 40
- From 28 Sept 2024 to the primary completion date, 28 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Claustrophobia or other psychiatric disorders.
- Other conditions deemed ineligible by the investigator.
Lab values
- Severe hepatic or renal dysfunction (serum creatinine \>3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal).
Other
- Women who are planning pregnancy, pregnant, or breastfeeding.
- Inability to lie supine for 30 minutes.
- Intolerance to any clinical procedures in the study.
Who the study is looking for
- Age ≥18 years, regardless of gender.
- Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months.
- At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Expected survival \>3 months.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| 100730 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.